Correlation of Risk Factors and Severity of Hypoxic-ischaemic Encephalopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The first aim of this study is to analyse perinatal risk factors leading to hypoxic ischaemic encephalopathy in term and near term neonates born in Switzerland who were admitted to the neonatal and intensive care units offering hypothermia therapy.

Further, investigators would like to analyse the influence of these perinatal risk factors on the severity of encephalopathy during and after hypothermia therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Systemic Hypothermia Improves Outcome of Hypoxic-Ischemic Encephalopathy

NCT00817401

Hypoxic-Ischemic Encephalopathy

COMPLETED PHASE1/PHASE2

Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy

NCT02826941

Neonatal Asphyxial Encephalopathy Hypoxic Ischemic Encephalopathy

COMPLETED PHASE2

Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)

NCT02349672

Hypoxic Ischemic Encephalopathy

COMPLETED

Hypothermia Therapy in Pediatric Cardiac Intensive Care Unit for Suspected for Brain Injury

NCT02395276

Congenital Heart Defects Brain Ischemia Hypoxia Brain +2 more

UNKNOWN NA

Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)

NCT05581927

Hypoxic- Ischemic Encephalopathy Whole-Body Hypothermia Brain Injury

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Encephalopathy of the neonate could have different aetiologies. Perinatal asphyxia leading to hypoxia-ischaemia is frequent ,1-2 per 1000 life born neonates are affected. Hypoxic ischaemic encephalopathy is one of the most important causes for adverse neurodevelopmental outcome, cerebral palsy, epilepsy and hearing and vision deficiencies in term and near term neonates. Til now, hypothermia therapy is the only therapy reducing the risk of adverse neurodevelopmental outcome and is nowadays standard of care. In this study investigators would like to analyse perinatal risk factors causing HIE and their influence on the Sarnat Score on day 1 and 3 of life (during hypothermia therapy) and on day 4 of life (after hypothermia therapy).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypoxic Ischaemic Encephalopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

risk factors

investigators will analyze if certain risk factors will influence the progression of the encephalopathy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* This study includes data of neonates suffering from hypoxic-ischaemic encephalopathy born with a gestational age \> 35 0/7 weeks, who were admitted to the neonatal and intensive care units in Switzerland between 2011-2013 and were treated with therapeutic hypothermia.

Exclusion Criteria

* Neonates with hypoxic-ischaemic encephalopathy, born with a gestational age \< 35 0/7 weeks or without hypothermia treatment or syndromal diseases or with malformations were excluded.
* Further, children without consent to research use were excluded.

Minimum Eligible Age

35 Weeks

Maximum Eligible Age

42 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No